Clinical Trials Logo
  1. Home
  2. Endometriosis
  3. NCT04461899

Changes in Serum antimüllerian Hormone Levels in Patients 3 and 12 Months After Endometrioma Sclerotherapy — ENDOPAL AMH  

Endometriosis Ovary Clinical Trial

Official title:
Changes in Serum antimüllerian Hormone Levels in Patients 3 and 12 Months After Endometrioma Sclerotherapy

Clinical Trial Summary

Endometriosis affects 6-10% of women in childbearing age. It is a heterogeneous disease with three different forms: superficial endometriosis (peritoneal), ovarian endometrioma and deep pelvic endometriosis (subperitoneal). Surgical management of endometriomas is justified in cases of significant clinical symptoms (like pain), especially in cases of resistance to medical treatment. Currently, laparoscopic cystectomy surgery is the recommended technique to treat ovarian endometrioma. However, it is now well demonstrated that this surgery significantly reduces the ovarian reserve. Ethanol sclerotherapy is an alternative technique used to treat ovarian endometriomas. Several studies demonstrated the effectiveness and safety of this treatment, particularly in terms of preserving fertility. Regarding these reassuring data, many clinicians changed their practices and propose this technique as a first-line surgery. Ovarian reserve comprises two elements: size of the primordial follicle stock and quality of the ovocytes. Antimüllerian hormone (AMH) has been shown to be the best marker of fertility. The aim of this study is to observe changes in AMH levels after endometrioma sclerotherapy. This study is conducted in the Hospices Civils de Lyon, in 3 different sites.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04461899
Study type Interventional
Source Hospices Civils de Lyon
Contact
Status Completed
Phase N/A
Start date July 9, 2020
Completion date April 14, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT06145438 - Comparing the Safety and Efficacy in the Use of Hormonal Therapy on Endometriosis Patients After Conservative Surgery Phase 3
Not yet recruiting NCT04401592 - The Role of Galectins in the Non-invasive Diagnosis of Endometriosis
Recruiting NCT04151433 - Conservative Endometrioma Surgery N/A
Withdrawn NCT03481842 - Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis Phase 1/Phase 2
Recruiting NCT06214260 - Menstrual Blood Proteomic Profile in Women With Endometriosis (PROTEO-ENDO) Study
Completed NCT05272930 - The Effect of Dionegest Use on the Frequency of Fibromyalgia in Endometriosis
Recruiting NCT04704115 - The Therapy of Large Endometrioma
Completed NCT03826355 - Impact on Ovarian Reserve According to the Type of Ovarian Endometrioma Excision: Laser Versus Conventional Cystectomy N/A
Recruiting NCT05976529 - A Multicenter, Observational Clinical Study of Dydrogesterone
Completed NCT04306276 - Pretreatment With Dienogest in Women With Endometriosis Undergoing in Vitro-fertilization After a Previous Failed Cycle
Completed NCT05348070 - Comparison of Operated Ruptured and Non-ruptured Endometriomas
Not yet recruiting NCT04491305 - EHP-5 in Preoperative Assessment in Women With Endometriosis
Completed NCT06207448 - Deep Infiltrating Endometriosis : Laparoscopic Nerve-sparing Surgery and Use of Neutral Argon Plasma
Active, not recruiting NCT03430609 - Ovarian Function After Use of Various Hemostatic Techniques During Treatment for Endometrioma N/A